March 19, 2012
Announcement no. 4

The NGAL test registered for diagnostic use in China

The first of BioPorto's distribution partners in China has obtained registration certification for the NGAL test through the Chinese health authorities (the State Food and Drug Administration, SFDA). This certification covers the use of the NGAL test for diagnosing acute kidney injury and is valid in every province of China.

BioPorto's partner has taken the next step of initiating the applications required for determining the public reimbursement for the use of the test. The procedure for the processing of reimbursement applications differs from one province to another and is initially being started in Beijing and Shanghai. The first agreements concerning public reimbursement for the use of the NGAL test are expected to be obtained by the end of the year.

BioPorto's other partners in China are also expected to obtain registration certification in 2012.

Further details relating to the distribution of the NGAL test in China are available in the just-published 2011 Annual Report, announcement no. 3, issued today.

For further information, please contact:
Frank Harder, CFO
Thea Olesen, CEO
Tel.: +45 4529 0000, e-mail: investor@bioporto.com

About BioPorto
BioPorto develops and markets antibodies and antibody-based products, including assays for the diagnosis of diseases—for the benefit of individual patients and the effectiveness of the healthcare sector. The company has inter alia developed a method (NGAL) for the diagnosis and monitoring of acute renal injury. Within the focus areas of the company, it is BioPorto's strategy to develop new methods that can be protected by patents and used extensively in the diagnosis of a number of diseases. BioPorto was established in 2000 and has approximately 30 employees. The company's stocks are listed on the NASDAQ OMX in Copenhagen (symbol: BIOPOR).